- Home
- WYHG vs MDWD Comparison
WYHG vs MDWD Comparison
Compare WYHG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- MDWD
- Stock Information
- Founded
- WYHG 1915
- MDWD 2000
- Country
- WYHG China
- MDWD Israel
- Employees
- WYHG N/A
- MDWD N/A
- Industry
- WYHG
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- WYHG
- MDWD Health Care
- Exchange
- WYHG NYSE
- MDWD Nasdaq
- Market Cap
- WYHG 222.6M
- MDWD 184.8M
- IPO Year
- WYHG 2024
- MDWD 2014
- Fundamental
- Price
- WYHG $5.24
- MDWD $17.94
- Analyst Decision
- WYHG
- MDWD Strong Buy
- Analyst Count
- WYHG 0
- MDWD 1
- Target Price
- WYHG N/A
- MDWD $25.00
- AVG Volume (30 Days)
- WYHG 353.7K
- MDWD 56.2K
- Earning Date
- WYHG 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- WYHG N/A
- MDWD N/A
- EPS Growth
- WYHG 10.09
- MDWD N/A
- EPS
- WYHG 0.27
- MDWD N/A
- Revenue
- WYHG $144,231,605.00
- MDWD $19,720,000.00
- Revenue This Year
- WYHG N/A
- MDWD $30.16
- Revenue Next Year
- WYHG N/A
- MDWD $18.44
- P/E Ratio
- WYHG $5.05
- MDWD N/A
- Revenue Growth
- WYHG 9.73
- MDWD N/A
- 52 Week Low
- WYHG $3.55
- MDWD $10.06
- 52 Week High
- WYHG $5.35
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- MDWD 55.25
- Support Level
- WYHG N/A
- MDWD $16.51
- Resistance Level
- WYHG N/A
- MDWD $17.40
- Average True Range (ATR)
- WYHG 0.00
- MDWD 0.73
- MACD
- WYHG 0.00
- MDWD 0.01
- Stochastic Oscillator
- WYHG 0.00
- MDWD 56.62
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The company is mainly engaged in offering ready to eat and packaged meat dishes. Its product offerings include supreme crispy sausage, fully thin sausage, Chinese sausage, Dongguan Erba sausage, yellow scorpion sausage, alcohol sausage, and meat chop.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.